Nolan Sigal, MD PhD — President and CEO. Dr. Sigal, a serial entrepreneur, has spent over 25 years in the academic, pharmaceutical and biotechnology communities. His biotechnology experience includes President of Trellis Bioscience, Inc., Executive Vice President, Research and Development, and CSO at Cytokinetics, Inc. (CYTK) and Senior Vice President, Drug Discovery for Pharmacopeia, Inc. (PCOP), where he was one of Pharmacopeia’s founders. Prior to joining Pharmacopeia, Dr. Sigal held several management positions during a 10 year period with Merck & Company Inc, including Executive Director of Immunology Research. Nolan graduated from Princeton University in 1971 with an A.B. in Chemistry.  Following completion of an M.D./Ph.D. program at the University of Pennsylvania and a pediatric residency, Dr. Sigal was on the faculty at the University of Toronto before moving to Merck. Most of his scientific research focused on understanding the biochemical events involved in the lymphocyte signal transduction.

Andrew Saxon, MD — Acting CSO. Dr. Saxon is Professor and former Chief of Clinical Immunology andAllergy at the UCLA School of Medicine. Dr. Saxon is a world-renowned expert in the cellular and molecular biology of human allergic disease. In addition to the developing the platforms Tunitas has licensed, Dr Saxon and his collaborators have made seminal discoveries on the mechanisms that control human allergic antibody (IgE) production and the role of environmental factors in development of the allergic response. Dr Saxon is chairman of the Allergy and Asthma Section of the Immune Tolerance Network.